Eden’s $91 first-month NAD headline does not include the required membership. Its current page lists a $39 first-month membership that renews at $99/month, with medication billed separately.
That makes the comparison with CoreAge more involved than subtracting two advertised starting prices. CoreAge is our featured commercial partner; the analysis below concerns disclosed costs and care questions, not a proven clinical advantage.
Eden’s displayed first-month subtotal is $130 from medication plus membership; its full renewal remains unconfirmed. Compare itemized totals, not the $91 medication headline alone.
Build the first-month total from the footnote
For the displayed Eden offer, $91 medication plus $39 membership produces a $130 first-month subtotal before any other applicable charges. This is arithmetic from the public offer, not a completed checkout quote. The page does not establish the later medication price.
CoreAge’s offer page shows $99, while its product page separately starts at $93/month and states no membership fees. Confirm the selected offer and full amount due rather than assuming every advertised figure is available on the same terms.
The ongoing Eden total is still incomplete
Eden’s membership renewal is disclosed at $99/month, but that is not the entire ongoing NAD bill. Medication remains separate, so an ongoing comparison needs the medication renewal as well. A first-month discount cannot answer that question.
The Eden review records the current footnote. Ask whether stopping medication also stops membership, when each renewal occurs, and whether either charge becomes nonrefundable before shipment.
Compare what the clinical fee actually includes
A membership can pay for access to a broader service without guaranteeing a prescription. Eden’s page explicitly separates membership from medication eligibility. Ask what care is available if NAD is not prescribed and what happens to the initial payment.
For CoreAge, ask what the included evaluation and follow-up cover under the selected plan. A no-membership statement does not eliminate the need to understand the clinical relationship or the recurring medication terms.
Testing claims deserve their own review
Eden describes potency, sterility, endotoxin, and pH checks. Those are provider representations, not tests performed by NAD Atlas. Ask for the actual dispensing pharmacy and how the relevant quality information can be obtained.
FDA’s explanation of compounding applies regardless of the billing model: a compounded prescription is not FDA-approved. A more detailed testing description does not establish that the service improves the health outcome you want.
When the comparison becomes decision-ready
Obtain an itemized first charge, medication renewal, membership renewal if any, supply period, and cancellation process. Then compare the same prescribed route and the support available in your state.
The cost guide and subscription guide help organize those facts. Until Eden’s ongoing medication cost is supplied, a claimed long-term savings figure would be an assumption.
Sources & reading notes
Editorial source review updated September 19, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Eden: NAD+ Injection Provider advertises $91 first-month medication plus required $39 first-month membership. Membership renews at $99/month; medication renewal remains separate and unconfirmed.
- CoreAge Rx: current NAD+ offer Provider advertising; offer page displays $99/month. Checked September 19, 2026.
- CoreAge Rx: NAD+ Injectable product page Provider advertising; product page displays a different starting price of $93/month.
- FDA: compounding questions and answers Explains that compounded drugs are not FDA-approved.
- FDA: ingredients suitable for sterile compounding Safety notice describing reported reactions and ingredient-quality concerns.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.